Peritsiazin
When ATH:
N05AC01
Characteristic.
A piperidine derivative of phenothiazine.
Pharmacological action.
Neuroleptic, antipsychotic.
Application.
Psihopatii (excitable and hysterical type), psychopathic disorders of organic origin with a predominance of affect and behavior sthenic, psychopathic condition in schizophrenia (incl. geboidnye), paranoid state with organic, vascular, presenile and senile diseases, epilepsy with affective-explosive characterological symptoms and dysphoric states.
Contraindications.
Hypersensitivity, zakrыtougolynaya glaucoma, porphyria, prostate adenoma, toxic agranulocytosis history.
Restrictions apply.
Cardiovascular diseases, kidney and / or liver failure, epilepsy, Parkinson's disease, advanced age (It increases the risk of an excessive hypotensive effect and CNS depression).
Side effects.
From the nervous system and sensory organs: state of depression, extrapyramidal disorders, rannyaya dyskinesia (spasmodic torticollis, okulomotornыy crisis, Trizm), pozdnyaya dyskinesia.
Other: orthostatic hypotension, anticholinergic effects (dry mouth, constipation, Parez akkomodacii, urinary retention), impotence, frigidity, amenorrhea, galactorrhea, gynecomastia, hyperprolactinemia, weight gain, cholestatic jaundice, agranulocytosis, photosensitivity, allergic reactions.
Cooperation.
It enhances the effect of antihypertensive drugs, a depressing effect on the central nervous system tranquilizers, alcohol, analgesics, hypnotics and for narcosis.
Overdose.
Symptoms: parkinsonizm, coma.
Treatment: symptomatic.
Dosing and Administration.
Inside. Dose picked individually, initial daily dose is 5-10 mg, for patients with a heightened sensitivity — 2-3 mg; the average daily intake of 30-40 mg, maximum-50-60 mg; the reception frequency is 3-4 times a day. Most of the daily dose taken in the evening (in connection with the possible development of sleepiness). After reaching a stable effect gradually reduce the dose to individual support.
Precautions.
In the event of hyperthermia therapy immediately cease periciazine. Careful monitoring of patients for the treatment of epilepsy (in connection with a possible lowering epileptic threshold) and Parkinson's disease.
During the period of treatment can not drink alcoholic beverages.
In the period of treatment should refrain from activities, require high concentration and speed of psychomotor reactions, tk. may cause drowsiness, especially at the beginning of the course.
Extrapyramidal disorders and early dyskinesia may be weakened while taking anticholinergic antiparkinsonian, but these funds are contraindicated in tardive dyskinesia (possible deterioration).
